NO20083784L - Nytt sitratsalt av en indol derivativ og den farmasoytiske bruken derav - Google Patents

Nytt sitratsalt av en indol derivativ og den farmasoytiske bruken derav

Info

Publication number
NO20083784L
NO20083784L NO20083784A NO20083784A NO20083784L NO 20083784 L NO20083784 L NO 20083784L NO 20083784 A NO20083784 A NO 20083784A NO 20083784 A NO20083784 A NO 20083784A NO 20083784 L NO20083784 L NO 20083784L
Authority
NO
Norway
Prior art keywords
pharmaceutical use
citrate salt
indole derivative
salt
fresh citrate
Prior art date
Application number
NO20083784A
Other languages
English (en)
Norwegian (no)
Inventor
Anna-Lena Berg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083784L publication Critical patent/NO20083784L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20083784A 2006-02-02 2008-09-02 Nytt sitratsalt av en indol derivativ og den farmasoytiske bruken derav NO20083784L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02
PCT/SE2007/000086 WO2007089191A1 (en) 2006-02-02 2007-01-31 New citrate salt of an indole derivative and its pharmaceutical use

Publications (1)

Publication Number Publication Date
NO20083784L true NO20083784L (no) 2008-10-13

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083784A NO20083784L (no) 2006-02-02 2008-09-02 Nytt sitratsalt av en indol derivativ og den farmasoytiske bruken derav

Country Status (24)

Country Link
US (2) US8008294B2 (ko)
EP (1) EP1981869A4 (ko)
JP (1) JP2009525324A (ko)
KR (1) KR20080098022A (ko)
CN (2) CN101379053A (ko)
AR (1) AR059225A1 (ko)
AU (1) AU2007210336B2 (ko)
BR (1) BRPI0706745A2 (ko)
CA (1) CA2641900A1 (ko)
EC (1) ECSP088647A (ko)
IL (1) IL192888A0 (ko)
MX (1) MX2008009719A (ko)
MY (1) MY146102A (ko)
NO (1) NO20083784L (ko)
NZ (1) NZ570849A (ko)
PE (1) PE20090192A1 (ko)
RU (1) RU2415137C2 (ko)
SA (1) SA07280004B1 (ko)
SG (1) SG169381A1 (ko)
TW (1) TW200800977A (ko)
UA (1) UA94251C2 (ko)
UY (1) UY30126A1 (ko)
WO (1) WO2007089191A1 (ko)
ZA (1) ZA200806725B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
BRPI0810216A2 (pt) * 2007-04-18 2014-10-21 Astrazeneca Ab Processo para a preparação de composto, composto, e, método de tratamento de distúrbio bipolar
WO2009017452A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl] ih- indole- 5 -carbonitrile citrate
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439593C (en) 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
CA2528805A1 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Also Published As

Publication number Publication date
EP1981869A1 (en) 2008-10-22
RU2008131906A (ru) 2010-03-10
ZA200806725B (en) 2009-07-29
US20090023732A1 (en) 2009-01-22
ECSP088647A (es) 2008-08-29
WO2007089191A1 (en) 2007-08-09
NZ570849A (en) 2011-01-28
CN101378754A (zh) 2009-03-04
AU2007210336A1 (en) 2007-08-09
MX2008009719A (es) 2008-09-04
MY146102A (en) 2012-06-29
CA2641900A1 (en) 2007-08-09
US8008294B2 (en) 2011-08-30
SA07280004B1 (ar) 2011-10-29
AU2007210336B2 (en) 2011-03-24
UY30126A1 (es) 2007-09-28
AR059225A1 (es) 2008-03-19
US20070203137A1 (en) 2007-08-30
KR20080098022A (ko) 2008-11-06
UA94251C2 (ru) 2011-04-26
IL192888A0 (en) 2009-02-11
PE20090192A1 (es) 2009-03-20
EP1981869A4 (en) 2010-08-25
SG169381A1 (en) 2011-03-30
BRPI0706745A2 (pt) 2011-04-05
CN101379053A (zh) 2009-03-04
RU2415137C2 (ru) 2011-03-27
JP2009525324A (ja) 2009-07-09
TW200800977A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20075136L (no) Nye liposompreparater
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
TW200616953A (en) Indole, indazole or indoline derivatives
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
NO20083784L (no) Nytt sitratsalt av en indol derivativ og den farmasoytiske bruken derav
EA201001858A1 (ru) Гетероциклические производные мочевины для лечения бактериальных инфекций
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
NO20092067L (no) 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander
WO2007100282A8 (en) New salts of an indole derivative and their use in medicine
EA200700692A1 (ru) Пиридиновые производные индолин-2-она, их получение и их прменение в терапии
NO20075508L (no) Stannsoporfinpreparater og administrering
WO2009018367A3 (en) Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application